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Abstract. This study used a hybrid near-infrared diffuse optical instrument to monitor tumor hemodynamic
responses to chemoradiation therapy for early prediction of treatment outcomes in patients with head and
neck cancer. Forty-seven patients were measured once per week to evaluate the hemodynamic status of clin-
ically involved cervical lymph nodes as surrogates for the primary tumor response. Patients were classified into
two groups: complete response (CR) (n ¼ 29) and incomplete response (IR) (n ¼ 18). Tumor hemodynamic
responses were found to be associated with clinical outcomes (CR/IR), wherein the associations differed
depending on human papillomavirus (HPV-16) status. In HPV-16 positive patients, significantly lower levels
in tumor oxygenated hemoglobin concentration ([HbO2]) at weeks 1 to 3, total hemoglobin concentration at
week 3, and blood oxygen saturation (StO2) at week 3 were found in the IR group. In HPV-16 negative patients,
significantly higher levels in tumor blood flow index and reduced scattering coefficient (μ 0s) at week 3 were
observed in the IR group. These hemodynamic parameters exhibited significantly high accuracy for early pre-
diction of clinical outcomes, within the first three weeks of therapy, with the areas under the receiver operating
characteristic curves (AUCs) ranging from 0.83 to 0.96. © 2016 Society of Photo-Optical Instrumentation Engineers (SPIE) [DOI: 10
.1117/1.JBO.21.8.085004]
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1 Introduction
Head and neck cancer accounts for about 3% to 5% of all can-
cers in the United States.1 More than 90% of head and neck
cancers arise from the epithelium lining the sinonasal tract,
oral cavity, pharynx (oropharynx, nasopharynx, hypopharynx),
and larynx and show microscopic evidence of squamous differ-
entiation. Head and neck squamous cell carcinoma (HNSCC)
frequently spreads to the lymph nodes in the neck. The major
risk factors for HNSCCs are tobacco use, alcohol consumption,
and infection with human papillomavirus (HPV).2 HPV has
been found in head and neck cancers from all sites with a higher
prevalence in oropharynx cancer.3 In clinical practice, HPV-16
immunohistochemistry is recommended for the detection of
HPV DNA in tumor cell nuclei.
Radiation therapy is a principal modality in the treatment of
HNSCC and may be combined with chemotherapy, surgery, or
both according to the stage, size, and location of tumors.
Radiation therapy works by damaging the DNA of cancer cells,
ultimately resulting in cell death. The treatment can also cause
long-term changes in the vasculature mediated through inflam-
matory cytokines and other agents.4 When using X-ray beams
for therapy, the radiation effect is manifest mainly through an
indirect mechanism involving free radical formation within
the intracellular matrix that attacks tumor cells.5 The efficacy
of X-ray radiation therapy is known to be dependent on tumor
oxygen status. Hypoxic tumor cells can repair their DNA dam-
age more readily than euoxic cells where the damage is irrevers-
ible because of the interaction of tissue oxygen with free
radicals.6,7 Many tumors are hypoxic because of abnormal
vasculature, malignancy-related anemia, and/or high oxygen
consumption by tumor cells.7 Studies using polarographic elec-
trodes have shown pretreatment tumor hypoxia are associated
with significantly poor responses to radiation therapy when
compared to oxygenated tumors.8–11 However, in these studies,
some well-oxygenated tumors failed to respond while some
hypoxic tumors responded well, possibly due to the dynamic
changes during treatment in tumor oxygen status induced by
radiation. Therefore, repeated monitoring of individual tumor
hemodynamic status during therapy may provide predictive
information for treatment outcomes.
Tumor hemodynamics, however, are not routinely monitored
over the course of cancer therapy in clinical practice due to the
lack of appropriate technologies. Several methods exist for
the measurement of tissue oxygenation or blood flow in tumors.
The invasive polarographic electrode method provides a point
measurement of tumor oxygenation,8–11 but tends to produce
*Address all correspondence to: Guoqiang Yu, E-mail: guoqiang.yu@uky.edu 1083-3668/2016/$25.00 © 2016 SPIE
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inconsistent results in highly heterogeneous tissues. Imaging
modalities, such as positron emission tomography (PET),12
dynamic computed tomography (CT), 13 and dynamic magnetic
resonance imaging (MRI),14 provide structural and functional
information about tumors, but require large and costly instru-
mentation that limits their potential for routine use in clinic.
Moreover, some of these techniques (e.g., CT and PET) expose
patients to ionizing radiation.
Near-infrared (NIR) diffuse optical methods offer a noninva-
sive, portable, fast, and low-cost alternative for frequent mon-
itoring of tumor microvascular hemodynamics at the bedside
over the time course of treatment.15–18 For example, Sunar
et al. previously used a hybrid NIR diffuse optical instrument for
noninvasive measurements of tumor hemodynamic responses to
chemoradiation therapy in a small group of patients with
HNSCC.15 Tumors exhibited significant dynamic flow and oxy-
genation changes during the first four weeks of the treatment.
However, their study was limited by the small number of
patients examined (n ¼ 8) and only one patient out of 8 showed
a partial response to the treatment. It was, therefore, impossible
to draw a conclusion from this pilot study about the feasibility of
measuring tumor hemodynamics to predict treatment outcomes.
Our study aimed to investigate the accuracy of weekly hemo-
dynamic measurements in HNSCCs during chemoradiation
therapy for the prediction of treatment outcome in a relatively
large population (n ¼ 47). Previously, we have developed and
validated a hybrid diffuse optical instrument combining a com-
mercial frequency-domain NIR tissue oximeter (Imagent, ISS
Inc., IL) with a custom-designed diffuse correlation spectros-
copy (DCS) flowmeter, which allowed for simultaneous quan-
tification of blood flow and oxygenation in deep tissues up to
several centimeters.17–20 While access to the primary tumor vol-
ume of HNSCC is not always possible with this device due to
the limit of tumor location (e.g., inside oral cavity), we measured
instead clinically involved, shallow cervical lymph nodes as sur-
rogates for primary tumor responses because both primary
tumors and cervical lymph nodes were included in the radiation
treatment volume and a previous study showed that primary
tumors and their regional lymph node metastases in HNSCC
had comparable patterns of oxygenation.21 We monitored hemo-
dynamic characteristics of these cervical lymph nodes once per
week over the chemoradiation treatment period of 7 weeks and
investigated the accuracy of using tumor hemodynamic
responses to therapy for predicting one-year treatment outcomes
based on the receiver operating characteristic (ROC) curve and
the area under the ROC curve (AUC).
2 Methods and Materials
2.1 Hybrid Diffuse Optical Instrument for Monitoring
Tumor Hemodynamics
Our hybrid diffuse optical instrument combining a commercial
NIR tissue-oximeter (Imagent, ISS, IL) and a custom-designed
DCS flowmeter allows us to simultaneously measure tumor
blood flow and blood oxygenation (Fig. 1). The commercial
Imagent system used for tumor blood oxygenation measurement
is a spatially resolved frequency-domain system employing 16
laser diodes at 690, 750, 780, and 830 nm (four diodes for each
wavelength) modulated at 110 MHz as sources and one photo-
multiplier tube (PMT) as the detector.22 Tumor oxygenation is
measured using a fiber-optic probe consisting of 16 source fibers
coupled to the 16 laser diodes and one detector fiber connected
to the PMT [Fig. 1(a)]. The source fibers (diameter ¼ 400 μm)
are arranged at distances of 2.0, 2.5, 3.0, and 3.5 cm from the
detector fiber (diameter ¼ 2.5 mm). The Imagent system mea-
sures the reduced amplitudes and phase shifts of the modulated
light at the four wavelengths and four source–detector (S–D)
distances after the diffused light propagates through the tissue
[Fig. 1(b)].20,22 An analytical homogenous solution based on
semi-infinite tissue geometry for photon diffusion equation
exposes linear relationships between the phases/logarithmic
amplitudes and the S–D distances. By fitting the slopes of these
linear relationships using the spatially resolved method, tissue
absorption coefficient (μa) and reduced scattering coefficient
(μ 0s) can be extracted at each of four wavelengths.
22 The tissue
blood oxygenation including oxygenated-, deoxygenated-,
and total-hemoglobin concentrations (i.e., [HbO2], [Hb], and
THC ¼ ½HbO2 þ ½Hb) and blood oxygen saturation (StO2 ¼
½HbO2∕THC × 100%) can be then calculated from the mea-
sured μa at the four wavelengths.
20 The commercial Imagent
system has been previously used for the quantification of
tumor optical properties and oxygenation status.17,23
Details about DCS theory and instrumentation for tissue blood
flow measurements have been described elsewhere.17,24–26
Briefly, a laser diode delivers continuous-wave (CW) light at
785 nm with long coherence length (>5 m) through a source
fiber (diameter ¼ 200 μm) into the tissue. The motions of mov-
ing scatterers (primarily red blood cells in tissue microvascula-
ture) cause light intensity fluctuations that are collected by a
single-mode detector fiber (diameter ¼ 5 μm) placed on the tis-
sue surface within a certain distance from the source. The S–D
distance for DCS measurement used in this study is 2.5 cm
[Fig. 1(b)]. A single-photon-counting avalanche photodiode
(APD) connected to the detector fiber detects the temporal light
intensity fluctuation in a single speckle area on the tissue surface
and the APD output is sent to an autocorrelator board for calcu-
lating the normalized light intensity temporal autocorrelation
function, g2ðτÞ ¼ IðtÞ · Iðtþ τÞ∕IðtÞ2, where τ is the autocorre-
lation delay time. The normalized electric field temporal autocor-
relation function (g1) can be derived from the measured g2 using
the Siegert equation 27
EQ-TARGET;temp:intralink-;e001;326;323g2ðτÞ ¼ 1þ βjg1ðτÞj2; (1)
where β is a constant determined primarily by the collection
optics of the experiment. The unnormalized electric field tempo-
ral autocorrelation function (G1) satisfies the correlation diffusion
equation in highly scattering media.24 In a semi-infinite homo-
geneous medium, the analytical solution of correlation diffusion
equation can be expressed as24
EQ-TARGET;temp:intralink-;e002;326;226 1ðρ; τÞ ¼
vS0
4πD

e−KðτÞr1
r1
−
e−KðτÞr2
r2

; (2)
where ρ is the source–detector separation, r1 ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ρ2 þ z20
p
, and
r2 ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ρ2 þ ðz0 þ 2zbÞ2
p
. K2ðτÞ ¼ 3μaμ 0s þ μ 02s K20α

Δr2ðτÞ.
k0 ¼ 2πn∕λ is the wavenumber of the CW light in the medium.
z0 ≈ 1∕μ 0s and zb ¼ 23μs
1þReff
1−Reff
, where Reff is the effective reflection
coefficient to account for the index mismatch between tissue and
air: Reff ¼ −1.44n−2 þ 0.71n−1 þ 0.668þ 0.064n, and n is the
ratio of refraction indices of tissue and air: n ¼ ntissue∕
nair ≃ 1.33. The normalized electric field temporal autocorrela-
tion function g1 can be obtained from G1
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EQ-TARGET;temp:intralink-;e003;63;291
g1ðρ; τÞ ¼
G1ðρ; τÞ
G1ðρ; 0Þ
¼

e−KðτÞr1
r1
−
e−KðτÞr2
r2

∕

e−Kð0Þr1
r1
−
e−Kð0Þr2
r2

: (3)
For the case of diffusive particle motion, the mean-square dis-
placement

Δr2ðτÞ of the moving scatterers in a delay time τ
is

Δr2ðτÞ ¼ 6DBτ, where DB is an effective diffusion coeffi-
cient of the moving scatterers. An α term (0 to 1) is added to
account for the fact that not all scatterers in tissue are dynamic
and is defined as the ratio of moving scatterers to total scatterers.
The combined term αDB is referred to as the blood flow index
(BFI) in biological tissues and is derived by fitting the measured
autocorrelation function to the analytical solution of g2, based on
Eqs. (2) and (3).17,18
DCS has been extensively validated against other stan-
dards 28,29 and has been used to detect tumor-to-normal flow con-
trasts in human breast cancers30,31 and to determine hemodynamic
effects of radiation therapy on human head and neck
cancers.15,16
For this study, we constructed a hybrid fiber-optic probe
by adding the source and detector fibers for DCS measurement
onto the Imagent probe [Fig. 1(b)]. As mentioned earlier, the S–
D distances for DCS and Imagent were 2.5 cm and 2.0 to 3.5 cm,
respectively, allowing for the detection of a tumor >2 cm in
size.16 Computer-controlled transistor–transistor logic signals
were used to control the Imagent and DCS devices working
alternately; lasers for DCS and Imagent measurements were
turned on sequentially to avoid the light interference between
the two measurements [Fig. 1(a)]. The sampling time for a com-
plete frame of blood flow and oxygen measurements is ∼4 s
(0. 25 Hz).
Our previous investigations have revealed that μa and μ 0s can
significantly affect the accuracy of DCS flow quantifica-
tions.17,18 Thus, μa and μ 0s measured by the Imagent at 780 nm
(close to the 785-nm laser used for DCS flow measurements)
were used as inputs for calculating BFI [see Eq. (2)]. The
final outputs from this hybrid instrument included μa, μ 0s ,
[HbO2], [Hb], THC, StO2, and BFI.
Fig. 1 Hybrid Imagent/DCS instrument for simultaneously measuring tumor oxygenation and blood flow
during chemoradiation therapy: (a) schematic of hybrid instrument, (b) fiber-optic probe, (c) chemoradia-
tion therapy protocol and measurement procedure, and (d) optical measurement (left) using a hybrid
Imagent/DCS instrument (right).
Journal of Biomedical Optics 085004-3 August 2016 • Vol. 21(8)
Dong et al.: Diffuse optical measurements of head and neck tumor hemodynamics for early prediction. . .
2.2 Patient Characteristics and Treatment Protocol
Fifty-six patients (n ¼ 56) with head and neck tumors under-
going chemoradiation therapy participated in this study with
the signed consents approved by the University of Kentucky
Institutional Review Board. Based on the detection limitation
in tumor size for optical measurements,16 we included Stage
III-IVb SCCHN with a cervical lymph node>2 cm in the longi-
tudinal dimension. Tumor location and size were identified by
MRI, CT, and/or ultrasound imaging. Patients with supraclavic-
ular adenopathy were not enrolled as there was a possibility of
the primary origin from other sites in the chest such as lung or
esophagus.
Each patient received daily fractional radiation over 7 weeks.
Both primary tumor and cervical lymph node were included in
the radiation treatment volume. A total dose of 70 Gy was deliv-
ered in once daily fractions of 2 Gy, and in the form of high-
energy X-ray beams (6 MV) produced by a medical linear accel-
erator (Clinac 21EX, Varian Medical Systems). Radiotherapy in
combination with traditional chemotherapy was applied on
these patients. The cisplatin was given at 100 mg∕m2 on Day
1 and Day 22 of radiation. The role of chemotherapy (cisplatin)
in head/neck cancer was to increase the incidence of double
strand breaks (radiosensitization) and decrease the incidence
of metastatic diseases.
2.3 Experimental Protocols
Prior to treatment, HPV-16 status was examined by immunohis-
tochemistry for most patients.32 The biggest clinically involved
cervical lymph node was identified by MRI or CT imaging as
the measured target and then the tumor node volume and loca-
tion were quantified. The optical measurement protocol con-
sisted of a pretreatment measurement as baseline and weekly
measurements (once per week) over the entire treatment period
of 7 weeks [Fig. 1(c)]. Before each optical measurement, an
ultrasound machine (Mindray M5, China) was used to verify
the location and size of the tumor node. Prior to each measure-
ment, the Imagent system was calibrated on a solid phantom
with known optical properties (μa and μ 0s).
The optical measurement was then continuously taken by
placing the hybrid fiber-optic probe on the skin of the selected
lymph node [Fig. 1(d)] for 3 min with a sampling rate of
0.25 Hz, followed by taking a measurement on the forearm
flexor muscle for 2 min as a control measurement for compari-
son. We took the control measurements on patients’ forearm
muscles because their forearms were outside the radiation beam
and thus less influenced by radiation treatment. This measure-
ment protocol allowed us to compare the sensitivities of using
local tumor hemodynamics and global tissue hemodynamics
for the prediction of treatment outcomes. Data obtained over
the measurement period were averaged and mean values
were used to represent tumor/muscle optical properties and
hemodynamics.
Clinical outcome assessments such as tumor volume change,
local control, remote metastasis, and/or local recurrence with
repeat CT scans were conducted every 3 to 4 months after com-
pletion of chemoradiation therapy. Since the majority of treat-
ment failures occur in the first 6 months (up to 80%), we
reported control rates at 12 months even though clinical evalu-
ation of response for further intervention was carried out at 10 to
12 weeks post PET scan. Based on clinical outcomes within 1
year after completing chemoradiation therapy, patients were
classified into two groups: (1) a complete response (CR)
group with disappearance of all target lesions and (2) an incom-
plete response (IR) group with appearance of distant metastasis
and/or local recurrence.
2.4 Data Analysis and Presentation
Although 56 patients were measured, two patients do not have
one-year follow-up results of treatment outcome yet. Among
these 54 patients with treatment outcomes, two were withdrawn
from the study at the request of patients and five did not have
pretreatment measurements due to instrument issues. Therefore,
47 patients in total were included for our data analysis (see
Table 1).
Table 1 Patient/tumor characteristics based on treatment outcomes
(IR versus CR).a
All patients
(n ¼ 47)
CR patients
(n ¼ 29)
IR patients
(n ¼ 18) p-value
Age 0.42
mean SE
(years)
57.77 1.16 58.52 1.40 56.56 2.00
Gender 0.089
Male 40 27 (93.10) 13 (72.22)
Female 7 2 (6.90) 5 (27.78)
Primary tumor
site
0.90
Base of tongue 17 11 (44.00) 6 (37.50)
Larynx 9 5 (20.00) 4 (25.00)
Tonsil 15 9 (36.00) 6 (37.50)
Unknown
primary
6 4 2
Tumor stage 0.44
Txþ T0-2 19 13 (44.83) 6 (33.33)
T3-4 28 16 (55.17) 12 (66.67)
Tumor node size 0.65
mean SE
(cm3)
39.55 5.82 37.42 5.83 42.97 11.89
Cutaneous
tissue thickness
0.72
mean SE (mm) 11.22 0.92 11.48 0.86 10.79 1.95
HPV-16 status 1.00
Positive 26 16 (69.57) 10 (66.67)
Negative 12 7 (30.43) 5 (33.33)
Unknown status 9 6 3
aValues in brackets indicate the percentages of patients calculated by
excluding those with unknown status.
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The optical measurements over the entire treatment courses
of 7 weeks were not always available for each individual due to
patient-related issues such as side effects of treatment, fatigue,
noncompliance with chemoradiation regimen or due to time
constraints of obtaining measurements and modification of
treatment schedules as a consequence of temporary breakdown
in radiation therapy equipment. Therefore, we marked the num-
ber of valid measurements at each time point in figures. Data
obtained beyond 4 weeks of the treatment were also not reported
because the majority of tumor nodes became too small (due to
the chemoradiation therapy) to be visible/measurable by our
optical technique.
Two-sample t-tests were used to compare the differences
between groups in continuous variables including age, tumor
node size, and cutaneous tissue thickness above the tumor.
Chi-square or Fisher’s exact tests were used in categorical var-
iables including gender, tumor site, tumor stage, and HPV-16
status. To compare the time course tumor hemodynamic
responses to therapy between the IR and CR groups and
between HPV-16 positive and HPV-16 negative groups, we
used linear mixed models 33 with fixed effects of time (as cat-
egorical), group (IR/CR or HPV-16 positive/HPV-16 negative),
and their interaction and banded covariance structures. Based on
the linear mixed model for each hemodynamic parameter, an
overall test was first constructed to assess whether there were
differences in that parameter between groups at any time
point. In the case of a significant overall test, post hoc pairwise
comparisons were then conducted at each time point and the
Holm’s procedure was used to adjust for multiple comparisons.
A p-value <0.05 was considered significant.
The predictive values of different optical measurement
parameters can vary over time. The ROC curves were con-
structed and the areas under the ROC curves (AUCs) were cal-
culated to evaluate the accuracy of various measured parameters
at different weeks for predicting treatment outcomes (CR/IR).
The ROC curve is commonly used to evaluate the accuracy
of a continuous marker for the prediction of a binary outcome,
and it is constructed by plotting the sensitivity against 1-spec-
ifity for all possible thresholds of the marker. The AUC corre-
sponding to an ROC curve is used as an overall measure to
quantify the accuracy. The bootstrap method 34 with 500 boot-
strap samples is used to obtain the 95% confidence interval (CI)
of the AUC. A 95% CI of AUC not including 0.5 indicates a
significant result.
The statistical analyses were performed by SAS 9.3 and R
software version 3.0.1. Particularly, the ROCR package was
used to calculate the AUC.
3 Results
The differences in tumor hemodynamic responses to chemora-
diation therapy between the IR and CR groups were first com-
pared without considering the effects of HPV-16 status
(Sec. 3.1). We then refined comparisons by separating patients
into an HPV-16 positive group or an HPV-16 negative group,
and reported the results in Secs. 3.2 and 3.3, respectively.
Based on these results, we summarized predictive values of
the measured parameters for one-year treatment outcomes
(Sec. 3.4). Finally, we compared the differences in tumor hemo-
dynamic responses and treatment outcomes between the HPV-
16 positive and HPV-16 negative groups (Sec. 3.5).
3.1 Comparison of Tumor Hemodynamic
Responses Between the IR and CR Groups in
All Patients
Figure 2 shows the dynamic changes of optical properties and
tissue hemodynamics over the treatment period of the first 4
weeks, measured in all tumor nodes (n ¼ 47) without consider-
ing HPV-16 status. Overall, there were significant differences
in [HbO2] [Fig. 2(b)], THC [Fig. 2(c)], and StO2 [Fig. 2(f)]
Fig. 2 Averaged values (means standard errors) of hemodynamic and diffuse optical parameters in
tumor nodes without considering HPV-16 status grouped by IR and CR: (a) BFI or αDB, (b) oxygenated
hemoglobin concentration ([HbO2]), (c) THC, (d) reduced scattering coefficient (μ 0s), (e) deoxygenated
hemoglobin concentration ([Hb]), and (f) blood oxygen saturation (StO2) in tumor nodes at different
weeks. Note that p-values derived from the linear mixed-effects model for overall differences between
the IR and CR groups are shown. The numbers shown at each week represent the valid measurements in
IR and CR patients, respectively.
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between the IR and CR groups (p ¼ 0.001; 0.012, and 0.009,
respectively). However, post hoc pairwise tests did not find
any significant difference in any parameter at any measurement
time point between the IR and CR groups.
For control measurements in forearms, no significant
differences either over the entire treatment period or at any
measurement time point were found between the IR and CR
groups (data are not shown).
There were no significant differences between the IR and CR
groups prior to the treatment in age, gender, tumor site, tumor
stage, tumor node size, cutaneous tissue thickness above the
tumor, and HPV-16 status (Table 1).
3.2 Comparison of Tumor Hemodynamic
Responses Between the IR and CR Groups in
HPV-16 Positive Patients
Dynamic changes of optical properties and tissue hemodynam-
ics in tumor nodes of HPV-16 positive patients (n ¼ 26) in
response to chemoradiation therapy are summarized in Fig. 3.
Overall, there were significant differences in [HbO2] [Fig. 3(b)],
THC [Fig. 3(c)], and StO2 [Fig. 3(f)] between the IR and CR
groups (p < 0.0001, p ¼ 0.0007, p ¼ 0.0005, respectively).
Post hoc pairwise tests demonstrated that the IR group had
significantly lower levels in [HbO2] at weeks 1, 2, and 3
Fig. 3 Averaged values (means standard errors) of hemodynamic and diffuse optical parameters in
HPV-16 positive patients grouped by IR and CR: (a) BFI (αDB), (b) [HbO2], (c) THC, (d) μ 0s, (e) [Hb], and
(f) StO2 in tumor nodes at different weeks. Note that p-values derived from the linear mixed-effects model
for overall differences between the IR and CR groups are shown. The numbers shown at each week
represent the valid measurements in IR and CR patients, respectively. Significant differences at 0.01
and 0.05 levels between groups derived from pairwise comparisons at different time points are indicated
with ** and *, respectively.
Fig. 4 Averaged values (means standard errors) of hemodynamic and diffuse optical parameters in
tumor nodes in HPV-16 negative patients grouped by IR and CR: (a) BFI (αDB), (b) oxygenated hemo-
globin concentration ([HbO2]), (c) total hemoglobin concentration (THC), (d) reduced scattering coeffi-
cient (μ 0s), (e) deoxygenated hemoglobin concentration ([Hb]), and (f) blood oxygen saturation (StO2) in
tumor nodes at different weeks. Significant differences at 0.01 and 0.05 levels between groups derived
from pairwise comparisons at different time points are indicated with ** and *, respectively.
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(p ¼ 0.02; 0.03, and 0.002, respectively) [Fig. 3(b)], in THC at
week 3 (p ¼ 0.02) [Fig. 3(c)], and in StO2 at week 3
(p ¼ 0.0004) [Fig. 3(f)], compared to the CR group.
For the control measurements in forearms, no significant
differences either over the entire treatment period or at any
measurement time point were found between the IR and CR
groups (data are not shown).
3.3 Comparison of Tumor Hemodynamic
Responses Between the IR and CR Groups in
HPV-16 Negative Patients
Figure 4 shows the dynamic changes of optical properties and
tissue hemodynamics in tumor nodes in response to chemora-
diation therapy in HPV-16 negative patients (n ¼ 12).
Overall, there were significant differences in BFI [Fig. 4(a)]
and μ 0s [Fig. 4(d)] between the IR and CR groups (p ¼ 0.046
and 0.01, respectively). Post hoc pairwise tests demonstrated
that the mean values of BFI and μ 0s at week 3 (p ¼ 0.01 and
0.02, respectively) in the IR group were significantly higher
than those in the CR group.
In HPV-16 negative patients, only forearm StO2 values in the
IR group showed an overall significantly lower level than the
CR group (p ¼ 0.04, data are not shown). However, post hoc
pairwise tests did not find any significant difference in forearms
at any measurement time point between the IR and CR groups.
3.4 Accuracy of Tumor Hemodynamic Parameters
for Predicting Treatment Outcomes
To evaluate the accuracy of hemodynamic parameters over the
treatment period for the prediction of treatment outcomes, we
calculated time-specific ROC curves and AUCs of these optical
measurements obtained at different weeks. Table 2 summarizes
the ROC results for the parameters showing predictive ability
to differentiate IR tumors from CR tumors. Parameters italicized
in this table are considered to have good predictive ability for
treatment outcomes, with the AUCs ranging from 0.83 to 0.96.
Table 2 Summary of time-specific AUC estimates (95% confidence interval) of the measured parameters for the prediction of treatment outcomes
(IR or CR) in HPV-16 positive or negative patients.a
Baseline Week 1 Week 2 Week 3 Week 4
HPV-16 positive patients
[HbO2] 0.64 (0.40, 0.83) 0.87 (0.68, 1.00) 0.83 (0.59, 0.98) 0.87 (0.68, 1.00) 0.76 (0.49, 0.97)
THC 0.62 (0.38, 0.82) 0.82 (0.60, 1.00) 0.82 (0.60, 0.99) 0.83 (0.61, 0.97) 0.74 (0.47, 1.00)
StO2 0.66 (0.42, 0.89) 0.77 (0.52, 0.96) 0.68 (0.42, 0.90) 0.84 (0.63, 0.97) 0.66 (0.34, 0.94)
HPV-16 negative patients
BFI 0.57 (0.17, 0.93) 0.64 (0.28, 1.00) 0.77 (0.43, 1.00) 0.93 (0.72, 1.00) 0.70 (0.30, 1.00)
μ 0s 0.69 (0.28, 1.00) 0.86 (0.57, 1.00) 0.80 (0.45, 1.00) 0.96 (0.84, 1.00) 0.65 (0.18, 1.00)
aThe results italicized are considered to have good predictive ability for treatment outcomes.
Fig. 5 ROC curves and their associated areas under the curve (AUC) for discriminating tumors with IRs
or CRs. (a) and (b) [HbO2] at week 1 and week 3 in HPV-16 positive patients, (c) THC at week 3 in HPV-
16 positive patients, (d) StO2 at week 3 in HPV-16 positive patients, (e) BFI in HPV-16 negative patients
at week 3, and (f) μ 0s in HPV-16 negative patients at week 3.
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Figure 5 shows corresponding ROC curves of these parameters
for discriminating tumors with IRs or CRs.
Specifically in HPV-16 positive patients, [HbO2] provided
the best prediction of treatment outcomes at week 1 and
week 3 [AUC ¼ 0.87 (95% CI: 0.68 to 1.00)]. THC and StO2
also showed moderate predictions of treatment outcomes at
week 3 [AUC ¼ 0.83 (95% CI: 0.61 to 0.97) and AUC ¼ 0.84
(95% CI: 0.63 to 0.97), respectively]. In HPV-16 negative
patients, BFI and μ 0s provided excellent predictions of treatment
outcomes at week 3 [AUC ¼ 0.93 (95% CI: 0.72 to 1.00) and
0.96 (95% CI: 0.84 to 1.00), respectively].
3.5 Comparison of Tumor Hemodynamic
Responses and Treatment Outcomes Between
the HPV-16 Positive and Negative Patients
Overall, there were no significant differences in most of the mea-
sured optical parameters between the HPV-16 positive and neg-
ative groups, except pretreatment baseline [Hb] (p ¼ 0.001) in
tumors. Post hoc pairwise tests demonstrated that the HPV-16
negative group had a significantly (p ¼ 0.01) higher level in
tumor [Hb] (19.69 1.71 μM) at pretreatment baseline (week
0) compared to the HPV-16 positive group (14.59 0.85 μM).
There were no significant differences between the HPV-16
positive and negative groups in age, gender, tumor stage, tumor
node size, and cutaneous tissue thickness above the tumor,
but significant difference was found in primary tumor site
(p < 0.001).
An insignificantly (p ¼ 1.00) higher frequency of CR
(61.54%, 95% CI: 40.57% to 79.77%) was observed in HPV-
16 positive tumors than that in HPV-16 negative tumors
(58.33%, 95% CI: 27.67% to 84.83%).
4 Discussion and Conclusions
This study aimed to evaluate the accuracy of tumor hemo-
dynamic parameters measured noninvasively by the optical
techniques for early prediction of chemoradiation therapy out-
comes in patients with head and neck cancer. For this purpose,
we utilized a hybrid diffuse optical instrument developed in our
laboratory and measured dynamic changes in optical properties
and hemodynamics of local tumors and forearm muscles
(as global controls for comparison) prior to the treatment and
weekly over the treatment period of 7 weeks. We examined
the predictive values of multiple parameters measured in the
local tumors including BFI, μ 0s , [HbO2], [Hb], THC, and StO2
in relation to one-year treatment outcomes. In addition, we also
evaluated the influence of other factors on treatment outcomes
(i.e., IR or CR) including age, gender, tumor stage, tumor node
size, cutaneous tissue thickness above the tumor, and HPV-16
status.
No significant baseline differences before treatment in age,
gender, tumor site, tumor stage, tumor node size, cutaneous
tissue thickness, HPV-16 status, and optical measurement
parameters of local tumors and control muscles were observed
between the IR and CR groups (see Table 1 and Fig. 2), sug-
gesting the insignificant influence of these baseline factors on
treatment outcomes. Forearm hemodynamics did not show sig-
nificant difference between the IR and CR groups at any meas-
urement time point before and during treatment, indicating
insignificant impacts of chemoradiation therapy on tissues out-
side the radiation beam.
Based on the overall results from 47 patients, IR tumors
exhibited significantly lower levels in [HbO2], THC, and StO2
than CR tumors over the treatment period (see Fig. 2), which
agrees with previous observations that HNSCCs with insuffi-
cient oxygen had poor treatment outcomes.9,10 However, post
hoc pairwise tests could not find significant difference at any
specific measurement time point (see Fig. 2), making it difficult
to use these parameters measured at one time point to predict
treatment outcomes. Interestingly, after breaking down the
patients into two subgroups of HPV-16 positive and HPV-16
negative, post hoc pairwise tests found significant differences
in some of the measured parameters at certain measurement
time points between the IR and CR groups.
Specifically, in the subgroup of HPV-16 positive patients, IR
tumors demonstrated significantly lower levels of [HbO2] at
weeks 1 to 3 as well as THC and StO2 at week 3, compared to
CR tumors (see Fig. 3). By contrast, in the subgroup of HPV-16
negative patients, IR tumors showed significantly higher levels
in BFI and μ 0s at week 3, compared to CR tumors (see Fig. 4). All
these parameters measured during the early stage of the treat-
ment (within the first three weeks of treatment) exhibited
moderate to high accuracy in predicting one-year treatment out-
comes within each subgroup (see Table 2 and Fig. 5). Note,
however, that the pretreatment baseline levels of tumor hemo-
dynamics measured at week 0 in each subgroup did not show
any predictive values for treatment outcomes, indicating the
importance of repeated monitoring of hemodynamic changes
during therapy. In addition, because the number of HPV-16 pos-
itive tumors (n ¼ 26) measured in this study is much larger than
that of HPV-16 negative tumors (n ¼ 12) (see Table 1), it is not
surprising that overall tumor hemodynamic responses (see
Fig. 2) follow similar trends of hemodynamic changes in
HPV-16 positive tumors (see Fig. 3).
Several clinical studies have shown that HPV positive
HNSCCs have a more favorable outcome and greater response
to radiotherapy than HPV negative HNSCCs.35–37 In this study,
we observed an insignificantly higher frequency of having CRs
in HPV-16 positive tumors compared to that in HPV-16 negative
tumors (see Sec. 3.5). Such insignificance may be due to the
relatively small number of patients enrolled in this study.
However, it is unclear why and how HPV-16 status affects pre-
dictive capabilities of our measured parameters differently for
predicting treatment outcomes. For example, we found in this
study that [HbO2], THC, and StO2 showed predictive values
for treatment outcomes in HPV-16 positive tumors while BFI
and μ 0s provided the best prediction of treatment outcomes in
HPV-16 negative tumors. Although the differences between
HPV-16 positive and negative tumors in gene mutations,38 hypo-
xia,39 angiogenesis,40 metabolic profile,41 and adaptation to
hypoxia have been suggested to impact treatment outcomes,
pathogenic mechanisms underlying these differences remain
speculative or even contradictory.
Previous studies have demonstrated equal frequencies of
baseline hypoxic tumors between the HPV-positive and HPV-
negative patients, determined by Eppendorf electrode or PET/
CT.42–44 The only significant differences observed in our
study between the HPV-positive and HPV-negative patients
were the baseline levels of [Hb] and primary tumor sites,
which seemed to not significantly affect the treatment outcomes
(see Sec. 3.5).
Only a few studies have monitored dynamic tumor oxygena-
tion changes during the period of treatment in a small number of
patients.11,43 For example, Mortensen et al. conducted 18F-flu-
orozzomycin arabinoside (FAZA) PET/CT hypoxia imaging in
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HNSCC patients treated with radiotherapy.43 Static imaging was
obtained on all 40 patients prior to irradiation and the distribu-
tion of hypoxia among the HPV-positive and negative tumors
was not significantly different. Only 13 of the 40 patients had
a repeat FAZA PET/CT scan separated from the pretreatment
imaging by 14 to 24 days. The repeat imaging showed a general
decline in the hypoxic volume compared to the baseline hypo-
xia. In another pilot study using invasive polarographic needle
electrodes, Lyng et al.11 measured tumor pO2 before treatment
(n ¼ 11) and once a week during therapy (n ¼ 8). Significant
fluctuations in pO2 occurred during radiotherapy, and results
showed that progressive disease occurred among the patients
with highly hypoxic tumors, regardless of hypoxic fractions
before or after treatment. In addition to the limited numbers
of patients studied, another limitation of both studies was
that the authors did not report whether these hypoxic variations
induced by the therapy were associated with HPV positivity.
In this study, we took advantage of a noninvasive and port-
able NIR diffuse optical technique to repeatedly monitor
tumor hemodynamic changes over the long treatment period.
Significant changes in tumor hemodynamics were found during
the early stage of the treatment, which affected significantly the
treatment outcomes. In the subgroup of HPV-16 positive tumors,
[HbO2], THC, and StO2 increased during the first three weeks of
treatment, which were reasonably associated with complete
tumor responses to therapy (see Fig. 3). In contrast, in the sub-
group of HPV-16 negative tumors, there was no significant dif-
ference in local tumor oxygenation between the IR and CR
groups during chemoradiation therapy (see Fig. 4). Instead, sig-
nificantly higher levels of μ 0s and BFI were observed in HPV-16
negative tumors with IRs at week 3. High angiogenesis (asso-
ciated with high μ 0s
45) was previously found to be related to poor
local control rate in HNSCCs under radiotherapy.46,47 Dynamic
increases in tumor blood flow during radiotherapy were also
detected by dynamic CT and DCS in HNSCCs with IRs to
therapy.13,15 Therefore, we speculate that the significantly higher
levels of μ 0s and BFI observed in HPV-16 negative tumors with
IRs may be associated with more active angiogenesis, which
forms defective vascular networks, leading to blood leakiness
inside tumors and reduced oxygen supply. In addition, a higher
blood flow level may be attributed to a higher up-regulation of
vascular endothelial growth factor (VEGF) in IR tumor cells
than that in CR tumor cells, which promotes the survival of
endothelial cells and thereby radiation resistance.48 Also, higher
expression of endothelial nitric oxide in IR tumors may further
enhance blood perfusion, open up nonperfused vessels, and pro-
mote neoangiogenesis.13,49 Further comprehensive investiga-
tions are needed to understand why and how HPV-16 status
affects predictive values of different parameters for tumor
responses to chemoradiation therapy.
Nevertheless, results from our study suggest that dynamic
changes in tumor microenvironment during treatment signifi-
cantly influence treatment outcomes, and frequent measure-
ments of dynamic changes in tumor properties (e.g., μ 0s) and
hemodynamics (e.g., BFI, [HbO2], [Hb], THC, and StO2) dur-
ing chemoradiotherapy generate essential information for early
prediction of tumor responses to therapy. These hemodynamic
parameters exhibited significantly high accuracy (AUCs ranging
from 0.83 to 0.96) for early prediction of clinical outcomes
within the first three weeks of therapy.
Such predications, based on frequent optical measurements,
may ultimately be used to optimize individual therapeutic
outcomes at an early time of radiotherapy. For example, treat-
ment outcomes may be improved by dynamically promoting
oxygenation levels (e.g., hyperbaric oxygen therapy) in HPV-
16 positive tumors or inhibiting angiogenesis (e.g., anti-
VEGF antibody) in HPV-16 negative tumors.50
In summary, our diffuse optical measurements show the
promise for early (within the first 3 weeks of treatment) predic-
tion of chemoradiation therapy in patients with head and neck
cancer. Since HPV-16 status affects tumor response to therapy,
subgrouping patients based on HPV-16 status is necessary to
improve the predictive accuracy for treatment outcomes. More
patients are needed to increase statistical power of data analysis,
to develop a predictive model integrating multiple parameters
for further improving predictive accuracy, and to find optimal
thresholds of the parameters for validating the classifier. In addi-
tion, patients who are predicted to have an IR to chemoradiation
may be guided to alternative therapies (e.g., surgical removal of
tumors) resulting in a reduction of the side effects associated
with chemoradiation. Dynamic modification of tumor proper-
ties/hemodynamics based on frequent optical measurements
during chemoradiation therapy is also expected to optimize
treatment outcomes individually.
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